v3.26.1
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Total CVS Health Shareholders’ Equity
Common Shares
Treasury Shares
Common Stock and Capital Surplus
 [2]
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024     1,778          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024 [1]       (518)        
Balance at beginning of period at Dec. 31, 2024 $ 75,730 $ 75,560 $ 18 $ (36,818) [1] $ 49,661 $ 62,837 $ (120) $ 170
Shareholders' Equity [Roll Forward]                
Net income 1,782 1,779       1,779   3
Other comprehensive income (loss) 179 179         179  
Stock option activity, stock awards and other (in shares)     1          
Stock option activity, stock awards and other 176 176     176      
ESPP issuances, net of purchase of treasury shares (in shares) [1]       1        
ESPP issuances, net of purchase of treasury shares 83 83   $ 83 [1]        
Common stock dividends (848) (848)       (848)    
Other (decreases) increases in noncontrolling interests 8 0           8
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2025     1,779          
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2025 [1]       (517)        
Balance at end of period at Mar. 31, 2025 $ 77,110 76,929 $ 18 $ (36,735) [1] 49,837 63,768 59 181
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2025     1,787          
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2025 (516)     (516) [1]        
Balance at beginning of period at Dec. 31, 2025 $ 75,382 75,214 $ 18 $ (36,790) [1] 50,402 61,196 406 168
Shareholders' Equity [Roll Forward]                
Net income 2,957 2,943       2,943   14
Other comprehensive income (loss) (205) (205)         (205)  
Stock option activity, stock awards and other (in shares)     1          
Stock option activity, stock awards and other 277 277     277      
ESPP issuances, net of purchase of treasury shares (in shares) [1]       1        
ESPP issuances, net of purchase of treasury shares 84 84   $ 84 [1]        
Common stock dividends (857) (857)       (857)    
Other (decreases) increases in noncontrolling interests $ (1) 0           (1)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2026     1,788          
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2026 (515)     (515) [1]        
Balance at end of period at Mar. 31, 2026 $ 77,637 $ 77,456 $ 18 $ (36,706) [1] $ 50,679 $ 63,282 $ 201 $ 181
[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of March 31, 2026 and 2025, and December 31, 2025 and 2024.
[2] Common stock and capital surplus includes the par value of common stock of $18 million as of March 31, 2026 and 2025, and December 31, 2025 and 2024.